Swiss National Bank held its position in shares of Natus Medical Incorporated (NASDAQ:BABY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,100 shares of the medical equipment provider’s stock at the close of the second quarter. Swiss National Bank owned about 0.17% of Natus Medical worth $2,018,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in shares of Natus Medical by 137,510.8% during the 1st quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock valued at $161,874,000 after buying an additional 4,121,198 shares during the period. Virginia Retirement Systems ET AL lifted its holdings in shares of Natus Medical by 122.3% during the 2nd quarter. Virginia Retirement Systems ET AL now owns 26,900 shares of the medical equipment provider’s stock valued at $1,003,000 after buying an additional 14,800 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Natus Medical by 9.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 973,346 shares of the medical equipment provider’s stock valued at $36,307,000 after buying an additional 86,192 shares during the period. Ameritas Investment Partners Inc. bought a new position in shares of Natus Medical during the 1st quarter valued at $110,000. Finally, Kennedy Capital Management Inc. lifted its holdings in shares of Natus Medical by 12.9% during the 1st quarter. Kennedy Capital Management Inc. now owns 316,253 shares of the medical equipment provider’s stock valued at $12,413,000 after buying an additional 36,151 shares during the period. 92.65% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/swiss-national-bank-continues-to-hold-holdings-in-natus-medical-incorporated-baby/1611733.html.

Natus Medical Incorporated (NASDAQ BABY) opened at 40.10 on Friday. The stock’s 50 day moving average price is $34.89 and its 200 day moving average price is $36.02. The company has a market capitalization of $1.30 billion, a PE ratio of 69.50 and a beta of 0.95. Natus Medical Incorporated has a 12-month low of $31.65 and a 12-month high of $44.38.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.01. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. The business had revenue of $122.20 million during the quarter, compared to the consensus estimate of $121.99 million. During the same period in the previous year, the firm posted $0.39 earnings per share. The business’s revenue for the quarter was up 27.3% compared to the same quarter last year. On average, equities analysts anticipate that Natus Medical Incorporated will post $1.70 EPS for the current fiscal year.

BABY has been the topic of several research analyst reports. Zacks Investment Research raised Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, August 24th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. Natus Medical currently has an average rating of “Hold” and an average price target of $48.00.

In other news, Director William M. Moore sold 3,000 shares of Natus Medical stock in a transaction on Monday, August 14th. The shares were sold at an average price of $34.10, for a total transaction of $102,300.00. Following the completion of the sale, the director now directly owns 30,410 shares in the company, valued at $1,036,981. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the sale, the director now owns 50,850 shares of the company’s stock, valued at $1,788,394.50. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

Natus Medical Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.